Syringe

PDA Announces 2023 Drug Delivery Innovation Award Winners at Universe of Pre-Filled Syringes Conference

Retrieved on: 
Tuesday, October 17, 2023
Universe, Chicago Innovation Awards, Partnership, ANSI, Stevanato Group, Parenteral Drug Association, PDA, Automation, Caregiver, WMG, University of Warwick, Digital platform, Global Smoke-Free Partnership Award, Organization, Limited partnership, Bayer, Ecosystem, Education, Merck, Science, PFS, Syringe, Patient, Diluent, Pharmaceutical industry, EU

BETHESDA, Md., Oct. 17, 2023 /PRNewswire-PRWeb/ -- The Parenteral Drug Association (PDA) today announced the winners of the 2023 PDA Drug Delivery Innovation Awards during the opening plenary session of the 2023 PDA Universe of Pre-Filled Syringes and Injection Devices conference in Gothenburg, Sweden. Awardees were recognized for their technical innovations in advancing the field of bio/pharmaceutical manufacturing.

Key Points: 
  • BETHESDA, Md., Oct. 17, 2023 /PRNewswire-PRWeb/ -- The Parenteral Drug Association (PDA) today announced the winners of the 2023 PDA Drug Delivery Innovation Awards during the opening plenary session of the 2023 PDA Universe of Pre-Filled Syringes and Injection Devices conference in Gothenburg, Sweden.
  • The companies recognized for the 2023 PDA Drug Delivery Innovation Awards are well-deserving of this honor and I congratulate them for their achievements and tireless effort to move the industry forward.
  • PDA recognizes the award winners each year at its annual Universe of Pre-Filled Syringes and Injection Devices conference, which is held in the U.S. in even years and the EU in odd years.
  • The PDA Drug Delivery Innovation Awards were created in 2019 to recognize technical innovations advancing the field of bio/pharmaceutical manufacturing.

SHL Medical and Lifecore Biomedical enter co-marketing partnership agreement

Retrieved on: 
Tuesday, October 17, 2023
Partnership, Senior, SHL, Syringe, CDMO, Corporate development, Patient, Quality of life, Fine chemical

ZUG, Switzerland, Oct. 17, 2023 /PRNewswire/ -- SHL Medical ("SHL"), a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has entered into a non-exclusive co-marketing partnership agreement with Lifecore Biomedical (Nasdaq: LFCR) ("Lifecore"), a fully integrated Contract Development and Manufacturing Organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials.

Key Points: 
  • ZUG, Switzerland, Oct. 17, 2023 /PRNewswire/ -- SHL Medical ("SHL"), a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has entered into a non-exclusive co-marketing partnership agreement with Lifecore Biomedical (Nasdaq: LFCR) ("Lifecore"), a fully integrated Contract Development and Manufacturing Organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials.
  • SHL and Lifecore will, pursuant to the terms of its agreement, exchange knowledge and experience in their respective fields, enabling both companies to provide their customers unparalleled guidance in CDMO services and best-in-class options for drug delivery device development.
  • As the leader and pioneer of autoinjectors, SHL offers drug delivery device solutions and vertically integrated capabilities for the development, manufacturing, and final assembly of its autoinjector products.
  • "We are excited to partner with Lifecore to provide high-quality CDMO services matching SHL's own high-touch approach to servicing our customers."

SHL Medical and Lifecore Biomedical enter co-marketing partnership agreement

Retrieved on: 
Tuesday, October 17, 2023
Partnership, Senior, SHL, Syringe, CDMO, Corporate development, Patient, Quality of life, Fine chemical

ZUG, Switzerland, Oct. 17, 2023 /PRNewswire/ -- SHL Medical ("SHL"), a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has entered into a non-exclusive co-marketing partnership agreement with Lifecore Biomedical (Nasdaq: LFCR) ("Lifecore"), a fully integrated Contract Development and Manufacturing Organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials.

Key Points: 
  • ZUG, Switzerland, Oct. 17, 2023 /PRNewswire/ -- SHL Medical ("SHL"), a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has entered into a non-exclusive co-marketing partnership agreement with Lifecore Biomedical (Nasdaq: LFCR) ("Lifecore"), a fully integrated Contract Development and Manufacturing Organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials.
  • SHL and Lifecore will, pursuant to the terms of its agreement, exchange knowledge and experience in their respective fields, enabling both companies to provide their customers unparalleled guidance in CDMO services and best-in-class options for drug delivery device development.
  • As the leader and pioneer of autoinjectors, SHL offers drug delivery device solutions and vertically integrated capabilities for the development, manufacturing, and final assembly of its autoinjector products.
  • "We are excited to partner with Lifecore to provide high-quality CDMO services matching SHL's own high-touch approach to servicing our customers."

BD, Casella Complete Industry-First Pilot Recycling 40,000 Pounds of Used Medical Devices

Retrieved on: 
Monday, October 16, 2023
Health, Hospital, BDX, Recycling, NYSE, Becton, Dickinson and Company headquarters, ESG, Casella Waste Systems, Municipal solid waste, State, Becton, BD, Syringe, Medical device, Biodegradable waste, Needle, Plastic, Casella

FRANKLIN LAKES, N.J. and RUTLAND, Vt., Oct. 16, 2023 (GLOBE NEWSWIRE) -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Casella Waste Systems, Inc. (Nasdaq: CWST) (Casella), a solid waste, recycling, and resource management services company, today announced the most recent results of a recycling pilot to manage discarded syringes and needles that led to 40,000 pounds of medical waste being recycled and diverted from disposal.

Key Points: 
  • The medical waste was collected across a variety of health care facilities and all of the plastics were diverted from disposal and recycled.
  • The pilot also assessed technical feasibility of two types of technology – mechanical and advanced recycling – both showing favorable results in their ability to successfully recycle used medical devices for use in other products.
  • The teams will also increase focus to cover other types of medical materials for recycling, as well as reclaiming the used devices and returning them to the manufacturing process.
  • “This pilot showcases the strength of collaborative partnerships when it comes to sustainable material management practices,” said Casella Chairman and CEO, John W. Casella.

Sharp acquires Berkshire Sterile Manufacturing

Retrieved on: 
Thursday, October 5, 2023
Partnership, Engineering, Acquisition, STEM, BSM, Syringe, Growth, Mathematics, Clinical trial, Science, CDMO, Woman, Medical device, Pharmaceutical industry, Management, Sharp, Therapure BioPharma Inc

Lee, Massachusetts, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Sharp , a global leader in commercial pharmaceutical packaging and clinical trial supply services, has today announced the acquisition of Berkshire Sterile Manufacturing (BSM), a Massachusetts-based fill finish contract development and manufacturing organization (CDMO) for clinical and commercial sterile injectable products.

Key Points: 
  • Lee, Massachusetts, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Sharp , a global leader in commercial pharmaceutical packaging and clinical trial supply services, has today announced the acquisition of Berkshire Sterile Manufacturing (BSM), a Massachusetts-based fill finish contract development and manufacturing organization (CDMO) for clinical and commercial sterile injectable products.
  • The acquisition enables Sharp to now offer a fully integrated small-to-medium scale sterile injectable service offering for the biopharmaceutical industry.
  • Sharp’s existing clinical supply, packaging, and distribution solutions will complement BSM’s sterile manufacturing expertise.
  • Together, Sharp and BSM will offer global, integrated CDMO services to Biopharma customers from sterile drug product manufacturing to clinical trial services, commercial packaging, and distribution.

SHL Medical and Lifecore Biomedical enter co-marketing partnership agreement

Retrieved on: 
Tuesday, October 17, 2023
Partnership, Senior, SHL, Syringe, CDMO, Corporate development, Patient, Quality of life, Fine chemical

ZUG, Switzerland, Oct. 17, 2023 /PRNewswire/ -- SHL Medical ("SHL"), a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has entered into a non-exclusive co-marketing partnership agreement with Lifecore Biomedical (Nasdaq: LFCR) ("Lifecore"), a fully integrated Contract Development and Manufacturing Organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials.

Key Points: 
  • ZUG, Switzerland, Oct. 17, 2023 /PRNewswire/ -- SHL Medical ("SHL"), a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has entered into a non-exclusive co-marketing partnership agreement with Lifecore Biomedical (Nasdaq: LFCR) ("Lifecore"), a fully integrated Contract Development and Manufacturing Organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials.
  • SHL and Lifecore will, pursuant to the terms of its agreement, exchange knowledge and experience in their respective fields, enabling both companies to provide their customers unparalleled guidance in CDMO services and best-in-class options for drug delivery device development.
  • As the leader and pioneer of autoinjectors, SHL offers drug delivery device solutions and vertically integrated capabilities for the development, manufacturing, and final assembly of its autoinjector products.
  • "We are excited to partner with Lifecore to provide high-quality CDMO services matching SHL's own high-touch approach to servicing our customers."

SHL Medical and Lifecore Biomedical enter co-marketing partnership agreement

Retrieved on: 
Tuesday, October 17, 2023
Partnership, Senior, SHL, Syringe, CDMO, Corporate development, Patient, Quality of life, Fine chemical

ZUG, Switzerland, Oct. 17, 2023 /PRNewswire/ -- SHL Medical ("SHL"), a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has entered into a non-exclusive co-marketing partnership agreement with Lifecore Biomedical (Nasdaq: LFCR) ("Lifecore"), a fully integrated Contract Development and Manufacturing Organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials.

Key Points: 
  • ZUG, Switzerland, Oct. 17, 2023 /PRNewswire/ -- SHL Medical ("SHL"), a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has entered into a non-exclusive co-marketing partnership agreement with Lifecore Biomedical (Nasdaq: LFCR) ("Lifecore"), a fully integrated Contract Development and Manufacturing Organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials.
  • SHL and Lifecore will, pursuant to the terms of its agreement, exchange knowledge and experience in their respective fields, enabling both companies to provide their customers unparalleled guidance in CDMO services and best-in-class options for drug delivery device development.
  • As the leader and pioneer of autoinjectors, SHL offers drug delivery device solutions and vertically integrated capabilities for the development, manufacturing, and final assembly of its autoinjector products.
  • "We are excited to partner with Lifecore to provide high-quality CDMO services matching SHL's own high-touch approach to servicing our customers."

EQS-News: Gerresheimer AG: Gerresheimer on track to another strong financial year

Retrieved on: 
Tuesday, October 17, 2023
Obesity, EUR, EBITDA, Magazine, Administration, Syringe, Plastic, COVID-19, Growth, History, C-peptide, Statement, Cryptocurrency, Pharmaceutical industry, Bookkeeping

“We have successfully signed additional contracts with attractive terms for GLP-1 platforms,” says Dietmar Siemssen, CEO of Gerresheimer AG.

Key Points: 
  • “We have successfully signed additional contracts with attractive terms for GLP-1 platforms,” says Dietmar Siemssen, CEO of Gerresheimer AG.
  • Adjusted EBITDA saw a strong organic increase of 19.9% year on year in the first nine months of the financial year.
  • Gerresheimer expects the positive business performance to continue in the final quarter of the financial year 2023 and confirms its guidance for the full year.
  • Guidance for FY 2023 (for group level, currency-adjusted):
    Medium-term guidance (for group level, currency-adjusted):
    The Quarterly Statement is available on the Gerresheimer website here:

BD, Casella Complete Industry-First Pilot Recycling 40,000 Pounds of Used Medical Devices

Retrieved on: 
Monday, October 16, 2023
Needle, Health, Hospital, BDX, Recycling, NYSE, Becton, Dickinson and Company headquarters, ESG, Casella Waste Systems, Municipal solid waste, State, Becton, BD, Syringe, Medical device, Biodegradable waste, Plastic, Casella

FRANKLIN LAKES, N.J. and RUTLAND, Vt., Oct. 16, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Casella Waste Systems, Inc. (Nasdaq: CWST) (Casella), a solid waste, recycling, and resource management services company, today announced the most recent results of a recycling pilot to manage discarded syringes and needles that led to 40,000 pounds of medical waste being recycled and diverted from disposal.  

Key Points: 
  • These containers included a broad range of medical equipment and materials, primarily syringes and needles.
  • The pilot also assessed technical feasibility of two types of technology – mechanical and advanced recycling – both showing favorable results in their ability to successfully recycle used medical devices for use in other products.
  • The teams will also increase focus to cover other types of medical materials for recycling, as well as reclaiming the used devices and returning them to the manufacturing process.
  • "This pilot showcases the strength of collaborative partnerships when it comes to sustainable material management practices," said Casella Chairman and CEO, John W. Casella.

West to Present on Development of Large Volume Delivery Systems, Self-injection Devices, and Prefillable Syringe Component Expertise at the PDA Conference

Retrieved on: 
Monday, October 16, 2023
Universe, WST, Product management, Syringe, NYSE, West Pharmaceutical Services, Conference, PDA, Drug packaging, Medical device

EXTON, Pa., Oct. 16, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced participation in the 2023 PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Gothenburg, Sweden to showcase its leadership and expertise on industry challenges and trends in packaging and containment. 

Key Points: 
  • Expert presentations and posters offer thought leadership in drug delivery innovation, patient adherence and pharmaceutical manufacturing
    EXTON, Pa., Oct. 16, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced participation in the 2023 PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Gothenburg, Sweden to showcase its leadership and expertise on industry challenges and trends in packaging and containment.
  • "In the last three years, we have seen a tremendous number of changes in the industry such as increasing regulatory requirements, increasing quality standards and requests for higher performance drug packaging and devices.
  • As we celebrate our 100-year milestone, West continues to expand and advance our portfolio of high-quality drug delivery packaging and devices to provide system solutions to support increasingly more sensitive and complex molecules," says William Matakas, Vice President, Product Management, Elastomer and Container Closure Components at West.
  • West will highlight its industry expertise through several technical-focused PDA presentations and posters:
    For more information about West, please visit our website: www.westpharma.com .